Drug regulation and approval

Explanation

Statement 1 is correct. The fee-for-service model, which dominates much of Indian health care, rewards activity — the ordering of tests, prescriptions, and procedures — rather than restraint or sound clinical judgement. This structural misalignment is a recognised driver of overtreatment in health-system literature. Statement 2 is incorrect. Polypharmacy is not primarily an indicator of deliberate malpractice; it is largely a consequence of fragmented, specialist-heavy care where each clinician optimises one dimension of a patient's health without coordinating with other treating physicians. The concern is systemic — fragmentation of care and the absence of medication review mechanisms — not individual malfeasance. Falsely attributing polypharmacy solely to malpractice misunderstands the structural diagnosis. Statement 3 is correct. A strong primary care system, anchored by a general or family physician, can serve as the first point of contact, decide which problems genuinely require specialist expertise, reconcile multiple prescriptions from different specialists, and identify opportunities for deprescribing. This gatekeeping and coordination function is a well-established public-health principle for containing overmedication and unnecessary surgical interventions.

Explanation

Statement 1 is incorrect. Under India's stem cell regulatory framework—comprising the New Drugs and Clinical Trials Rules, 2019 and the ICMR-DBT National Guidelines for Stem Cell Research—stem cell therapy for conditions such as autism spectrum disorder (ASD) is not permissible as a routine clinical service merely on the basis of informed consent. It can only be administered within a duly approved and monitored research or clinical trial setting. Offering it as a clinical service outside such a setting is treated as illegal administration of a prohibited medical intervention. Statement 2 is correct. The New Drugs and Clinical Trials (NDCT) Rules, 2019, together with the ICMR-DBT National Guidelines for Stem Cell Research, constitute the primary regulatory architecture for stem cell interventions in India. They require prior regulatory approval—typically from CDSCO and/or an institutional ethics committee—before any clinical trial involving stem cell manipulation can be initiated. Statement 3 is correct. A randomised controlled trial design can raise serious ethical concerns when some eligible participants—including those already receiving an experimental therapy—might be assigned to a control arm and thereby lose access to the intervention. This concern is central to ethical standards in clinical research, including the Helsinki Declaration principles incorporated into Indian trial regulations, which require that participant welfare and the possibility of therapeutic benefit be safeguarded in trial design.

Explanation

All three pairs are correctly matched. First, a bioequivalence study is a regulatory tool that compares the rate and extent of absorption (bioavailability) of a generic drug with that of its reference branded product — this is a standard criterion used globally to establish interchangeability, recognised by bodies such as the WHO and CDSCO. Second, bioavailability refers to the rate and extent to which an administered drug enters the systemic circulation from the site of administration (typically the digestive tract for oral drugs) — this is the foundational pharmacokinetic concept underlying bioequivalence testing. Third, the WHO's guidance on generic medicines explicitly recognises that a bioequivalence study may be waived when both the generic and the reference product are pharmaceutically equivalent oral solutions containing the same active ingredient at the same molar concentration (subject to applicable excipient requirements) — this is precisely the scientific rationale under which regulators like CDSCO may approve an oral-solution generic without requiring a separate human bioequivalence study. Understanding these three definitions is central to evaluating disputes over generic drug approval in India's regulatory framework under the Drugs and Cosmetics Act, 1940, administered by CDSCO.

Explanation

Under India's drug pricing framework, the Drugs (Prices Control) Order (DPCO) empowers the NPPA to fix ceiling prices for scheduled formulations — essential medicines listed in the National List of Essential Medicines — that manufacturers cannot breach. Non-scheduled formulations (those outside the scheduled list) are not subject to direct ceiling prices but can be regulated through trade-margin rationalisation, whereby the NPPA caps the percentage mark-up a distributor or retailer may charge over the price to stockist (PTS), thereby controlling the MRP indirectly. Both pairs 1 and 2 are correctly matched under this framework. Pair 3 is wrong: compulsory licensing is not administered by the NPPA. It is a mechanism under the Indian Patents Act, 1970, administered by the Controller General of Patents, Designs and Trade Marks. Compulsory licensing allows a third party to manufacture a patented product without the patent holder's consent under specified conditions, but the NPPA has no role in granting or administering it.

Explanation

Under the Drugs (Prices Control) Order (DPCO), formulations are classified as 'scheduled' or 'non-scheduled.' For scheduled formulations, the NPPA fixes ceiling prices directly, and the applicable trade margin is 16% over the price to the retailer — making Pair 1 correctly matched. Non-scheduled formulations are not subject to direct price-ceiling control by the NPPA; instead, when the NPPA determines that excessive trade margins are being charged in public interest, it can invoke Trade Margin Rationalisation (TMR) to cap the margins across the supply chain — making Pair 2 correctly matched. Pair 3 is incorrectly matched: TMR does not work by fixing the manufacturer's ex-factory cost. Instead, it rationalises the markup applied at each stage of the distribution chain (manufacturer to stockist to retailer) by setting a cap on the percentage margin that can be charged over the Price to Stockist (PTS). Critics of the current TMR formula note that a 42.8% markup over PTS is still significantly higher than the 16% margin applicable to scheduled formulations, underscoring the conceptual distinction between direct price-ceiling control (scheduled) and trade-margin rationalisation (non-scheduled).

Explanation

All three pairs are correctly matched. First, under the DPCO 2013, 'scheduled formulations' are those included in Schedule I, which is drawn from the National List of Essential Medicines (NLEM) prepared by the Ministry of Health and Family Welfare — the NPPA fixes statutory ceiling prices for these drugs. Second, 'non-scheduled formulations' are those outside Schedule I; for these, manufacturers set the initial price and are permitted annual price increases of up to 10%, meaning an inflated starting price can compound over time without a ceiling-price check. Third, trade margin capping is a distinct regulatory power available to the NPPA under the DPCO — it caps the percentage mark-up that can be added across the supply chain (from manufacturer to stockist to retailer) and can be applied even to non-scheduled drugs, as demonstrated when the NPPA capped trade margins on 137 non-scheduled anti-cancer drugs. Understanding the distinction between these three instruments — ceiling prices (for scheduled drugs), annual price-increase caps (for non-scheduled drugs), and trade margin caps (applicable beyond scheduled drugs) — is central to understanding how the DPCO framework actually operates.

Explanation

Statement 1 is incorrect in its characterisation of NPPA's legal basis. NPPA is not a statutory body in the strict sense — it is an executive body (authority) set up by the Government of India through a Cabinet Resolution in 1997, deriving its regulatory functions from the Essential Commodities Act, 1955, and the Drugs (Prices Control) Order issued thereunder. It is a non-statutory (administrative/executive) authority, not a body created by a dedicated Act of Parliament. Conflating its powers with a statutory creation under DPCO misstates its constitutional character. Statement 2 is correct. Under the DPCO framework, ceiling prices for medicines listed in the National List of Essential Medicines (NLEM) — i.e., scheduled formulations — are determined through a market-based averaging methodology (simple average of all medicines in a dosage form with market share ≥ 1%), not through cost-based pricing. This market-based averaging formula is a well-established feature of Indian drug price regulation. Statement 3 is correct. Trade-margin rationalisation (TMR) is a distinct price-control mechanism applied to non-scheduled medicines (those outside the NLEM/scheduled list). Instead of fixing a manufacturer's price, TMR caps the percentage margin that the supply chain — distributors and retailers — can add over the manufacturer's price or landed cost. The anti-cancer drug example in recent news (a 30% trade-margin cap) illustrates precisely this mechanism: the intervention targets the distributor-to-retailer-to-patient markup, not the ex-factory price. This tool addresses the phenomenon where a medicine supplied at ₹2,700 carries an MRP of ₹27,000 due to uncapped supply-chain margins.

Explanation

Pair 1 is correctly matched: the US FDA's 'tentative approval' is a standard regulatory designation applied to generic drugs that meet all quality, safety, and efficacy requirements but cannot yet receive full approval because the originator (brand-name) product remains under patent protection. Once the patent expires or is otherwise resolved, tentative approval converts to full approval automatically. Pair 2 is correctly matched: Pre-exposure prophylaxis (PrEP) is indeed medicine taken by HIV-negative people who are at high risk of contracting HIV, administered before any potential exposure to prevent infection — this is the established public-health definition. Pair 3 is incorrectly matched: Bioequivalence does NOT require a generic to be chemically identical in molecular structure to the originator — that standard is called pharmaceutical equivalence or active pharmaceutical ingredient identity. Bioequivalence specifically means that the generic drug delivers the same amount of the active ingredient into the bloodstream at the same rate and extent (i.e., comparable pharmacokinetics — absorption, distribution) as the brand-name drug, producing the same therapeutic effect under the same conditions. The falsity in Pair 3 lies in confusing bioequivalence (a pharmacokinetic/comparative concept) with structural identity (a chemistry concept).

Explanation

Under the Drugs and Cosmetics Act, 1940, the Drugs Technical Advisory Board (DTAB) is the apex statutory technical body that advises both Central and State Governments on technical questions arising from the Act's administration — Pair 1 is correctly matched. The Drugs Consultative Committee (DCC) is a coordinating body that recommends uniform administration of the Act across States and facilitates coordination between the Centre and State Licensing Authorities — Pair 2 is correctly matched. A Government Analyst, however, is a notified official whose function is to test drug samples and certify whether a drug is of standard quality or Not of Standard Quality (NSQ) — essentially a quality-testing and reporting role. It is the Central Licensing Approving Authority (CLAA/DCGI) and State Licensing Authorities, not Government Analysts, that issue manufacturing licences and approvals — Pair 3 is incorrectly matched. The proposed amendment to the Drugs Rules, 1945 makes the Government Analyst's NSQ report the trigger for immediate licence suspension, reinforcing that the Analyst's role is evidentiary/reporting, not licensing.

Explanation

All three pairs are correctly matched. First, the NPPA is a statutory body that functions under the Department of Pharmaceuticals, which falls under the Ministry of Chemicals and Fertilizers — this administrative placement is a commonly tested distinction because the NPPA deals with medicines yet sits outside the Ministry of Health. Second, the Drug Price Control Order (DPCO), 2013 derives its authority from the Essential Commodities Act, 1955 — the ECA empowers the central government to control production, supply, and pricing of essential commodities, and pharmaceuticals are notified as such; this is a standard doctrinal confusion since candidates often associate drug pricing with health law rather than the ECA. Third, trade-margin rationalisation is a distinct price-control mechanism from scheduled-drug price-fixation: under scheduled price-fixation (covering drugs in the National List of Essential Medicines), NPPA directly caps the manufacturer's ceiling price using a market-based formula; under trade-margin rationalisation (applied to non-scheduled drugs including many anti-cancer formulations), NPPA caps the percentage markup that wholesalers and retailers may add to the manufacturer's price, thereby indirectly controlling the MRP without fixing the ex-factory price. These are two conceptually different instruments within the same DPCO, 2013 framework.

Explanation

Pharmacovigilance refers to the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects of medicines after they have been approved and are in widespread use — so Pair 1 is correctly matched. A label revision or warning update is a post-marketing regulatory action, not a pre-approval one — it is triggered when post-approval surveillance (such as analysis of adverse event reports and published clinical data) reveals new safety signals. Pair 2 incorrectly describes it as a pre-approval action, making it wrongly matched. An Adverse Event Reporting System (such as the US FDA's FAERS, or India's CDSCO's PvPI portal) is indeed a passive, voluntary/mandatory post-marketing reporting mechanism through which unexpected drug reactions are communicated to regulators — so Pair 3 is correctly matched. This is precisely the mechanism the FDA used in the GLP-1 drug case: it reviewed both published trial data and its electronic adverse event reporting system before updating the drug label.